Syn-Ake
A peptide mimicking the venom of the temple viper. Antagonises nicotinic acetylcholine receptors to soften expression lines.
Reversibly blocks nicotinic ACh receptors at the neuromuscular junction, reducing contraction depth in expression muscles.
- Reduces expression lines
- Faster onset than Argireline
- Documented in vivo data
What the evidence supports.
- All skin types
No notable contraindications reported.
Mid-routine serum or treatment step.
Concentration range in well-formulated products: 2%–4%
Year-round.
Marketed as 'natural Botox alternative', manage expectations; data is in vivo on volunteers, not RCT.
The research behind Syn-Ake.
Every claim on this page traces to published research. Findings below are drawn from randomized trials and systematic reviews, each links to the study on PubMed.
Journal of Drugs in Dermatology, 2019
Maturitas, 2017
Inflammation and Allergy Drug Targets, 2014
Annals of Internal Medicine, 2013
No flagged conflicts. Still, patch-test new actives.
Sign up to see how Syn-Ake fits your skin archetype and personalised protocol.